Literature DB >> 24320166

The Lake Wobegon effect: are all cancer patients above average?

Jacqueline H Wolf1, Kevin S Wolf.   

Abstract

CONTEXT: When elderly patients face a terminal illness such as lung cancer, most are unaware that what we term in this article "the Lake Wobegon effect" taints the treatment advice imparted to them by their oncologists. In framing treatment plans, cancer specialists tend to intimate that elderly patients are like the children living in Garrison Keillor's mythical Lake Wobegon: above average and thus likely to exceed expectations. In this article, we use the story of our mother's death from lung cancer to investigate the consequences of elderly people's inability to reconcile the grave reality of their illness with the overly optimistic predictions of their physicians.
METHODS: In this narrative analysis, we examine the routine treatment of elderly, terminally ill cancer patients through alternating lenses: the lens of a historian of medicine who also teaches ethics to medical students and the lens of an actuary who is able to assess physicians' claims for the outcome of medical treatments.
FINDINGS: We recognize that a desire to instill hope in patients shapes physicians' messages. We argue, however, that the automatic optimism conveyed to elderly, dying patients by cancer specialists prompts those patients to choose treatment that is ineffective and debilitating. Rather than primarily prolong life, treatments most notably diminish patients' quality of life, weaken the ability of patients and their families to prepare for their deaths, and contribute significantly to the unsustainable costs of the U.S. health care system.
CONCLUSIONS: The case described in this article suggests how physicians can better help elderly, terminally ill patients make medical decisions that are less damaging to them and less costly to the health care system.
© 2013 Milbank Memorial Fund.

Entities:  

Keywords:  NSCLC treatment; end-of-life care; hospice; physician/patient communication

Mesh:

Year:  2013        PMID: 24320166      PMCID: PMC3876187          DOI: 10.1111/1468-0009.12030

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  54 in total

1.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Authors:  Jean-Yves Douillard; Rafael Rosell; Mario De Lena; Francesco Carpagnano; Rodryg Ramlau; Jose Luis Gonzáles-Larriba; Tomasz Grodzki; Jose Rodrigues Pereira; Alain Le Groumellec; Vito Lorusso; Claude Clary; Antonio J Torres; Jabrail Dahabreh; Pierre-Jean Souquet; Julio Astudillo; Pierre Fournel; Angel Artal-Cortes; Jacek Jassem; Leona Koubkova; Patricia His; Marcello Riggi; Patrick Hurteloup
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer.

Authors:  Dimosthenis Antoniou; Kostas Kyprianou; George P Stathopoulos; Christos Skarleas; Georgia Kolitsi; Marinos Veslemes; John Dimitroulis; Pantelis Giamboudakis; Kostas Marosis; Ourania Armenaki; C Papageorgiou; Costas Katis
Journal:  Oncol Rep       Date:  2005-09       Impact factor: 3.906

Review 4.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Authors:  Robert L Comis
Journal:  Oncologist       Date:  2005-08

5.  Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors.

Authors:  Angelika Zabel; Stefanie Milker-Zabel; Christoph Thilmann; Ivan Zuna; Bernhard Rhein; Michael Wannenmacher; Jürgen Debus
Journal:  Lung Cancer       Date:  2002-07       Impact factor: 5.705

6.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Authors:  Paul Wheatley-Price; Keyue Ding; Lesley Seymour; Gary M Clark; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

8.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Authors:  Ulrich Gatzemeier; Anna Pluzanska; Aleksandra Szczesna; Eckhard Kaukel; Jaromir Roubec; Flavio De Rosa; Janusz Milanowski; Hanna Karnicka-Mlodkowski; Milos Pesek; Piotr Serwatowski; Rodryg Ramlau; Terezie Janaskova; Johan Vansteenkiste; Janos Strausz; Georgy Moiseevich Manikhas; Joachim Von Pawel
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

9.  Comparing hospice and nonhospice patient survival among patients who die within a three-year window.

Authors:  Stephen R Connor; Bruce Pyenson; Kathryn Fitch; Carol Spence; Kosuke Iwasaki
Journal:  J Pain Symptom Manage       Date:  2007-03       Impact factor: 3.612

10.  Inoperable brain metastases from non-small cell lung cancer: what part does whole brain radiotherapy play in standard treatment?

Authors:  Rachael Barton
Journal:  Thorax       Date:  2008-01       Impact factor: 9.139

View more
  3 in total

1.  Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.

Authors:  Michael Hoerger
Journal:  Death Stud       Date:  2015-08-27

2.  Commentary: "the Lake Wobegon effect, a natural human tendency to overestimate one's capabilities" (Wikipedia).

Authors:  Thomas J Smith
Journal:  Milbank Q       Date:  2013-12       Impact factor: 4.911

3.  Evaluation of a toolkit resource package to support positive workplace behaviours in relation to quality end-of-life care in Australian hospitals.

Authors:  Claire Hutchinson; Jennifer Tieman; Kim Devery
Journal:  BMJ Open Qual       Date:  2018-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.